epirubicin has been researched along with Myelodysplastic Syndromes in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alimonti, A; Carlini, P; Cognetti, F; Di Cosimo, S; Fabi, A; Ferretti, G; Nardoni, C; Papaldo, P; Ruggeri, EM | 1 |
| Bergh, J; Bliss, J; Bonneterre, J; Cesana, B; Coombes, RC; Fargeot, P; Folin, A; Fumoleau, P; Giuliani, R; Hery, M; Kerbrat, P; Nilsson, J; Onida, F; Piccart, M; Praga, C; Rogers, D; Shepherd, L; Therasse, P; Wils, J | 1 |
| Ferretti, G; Papaldo, P | 1 |
| Arbona, C; Benet, I; Comes, AM; García Clavel, B; García-Conde, J; Lluch, A; Martínez-Climent, JA; Marugán, I; Prósper, F; Solano, C; Vizcarra, E | 1 |
1 trial(s) available for epirubicin and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Does the concurrent use of anthracycline and granulocyte colony-stimulating factor influence the risk of secondary leukaemia in breast cancer women?
Topics: Acute Disease; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid; Middle Aged; Myelodysplastic Syndromes; Neoplasms, Second Primary; Risk Factors | 2005 |
3 other study(ies) available for epirubicin and Myelodysplastic Syndromes
| Article | Year |
|---|---|
Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Data Interpretation, Statistical; Epirubicin; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Randomized Controlled Trials as Topic; Risk Factors | 2005 |
Acute myeloid leukaemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
Topics: Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Epirubicin; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Proportional Hazards Models; Treatment Outcome | 2008 |
Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant; Chromosome Aberrations; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Leukemia; Middle Aged; Myelodysplastic Syndromes; Neoplasm Staging; Neoplasms, Second Primary; Postmenopause; Predictive Value of Tests; Premenopause; Transplantation, Autologous | 2000 |